Open-angle Glaucoma Market Share, Size, Trends and Forecast till 2030

1. Open-angle glaucoma (OAG) Market Insights, Epidemiology, and Market Forecast—2030 DelveInsight’s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast—2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. The current treatment management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred. Geography Covered • • • The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Open-angle glaucoma – Disease Understanding and Treatment Algorithm Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous

2. humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases. OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of OAG are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension. Open-angle glaucoma – Epidemiology The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type-Specific Diagnosed Prevalence of Open- Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030. As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence of OAG was observed forfemales, in comparison to males, in all the 7MM countries. DelveInsight’s analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this, it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG. Open-angle glaucoma – Drug Chapters This segment of the Open-angle glaucoma (OAG) report encloses the detailed analysis of marketed drugs and late- stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The treatment and market of OAG are dependent on the class of drugs, like prostaglandin analogs, beta- blockers, alpha-agonists, and carbonic anhydrase inhibitors. In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP – 716 (Sun Pharma), Trabodenoson (Inotek Pharmaceuticals), DE- 30A (Santen), and others. Prostaglandin derivatives, beta-blockers, Topical carbonic anhydrase inhibitors (CAIs), alpha2-adrenergic receptor agonists and Combination therapies are the most preferred classes for the treatment of open-angle glaucoma. In the United States, drugs of this class have been approved in the past few years like Vyzulta, Xelpros, TravatanZ, and a few others by the US FDA. Rhopressa which is marketed in both the US and Europe (Rhokiinsa), has recently completed the phase II trial in Japan. The company is looking to meet with Japan’s Pharmaceutical and Medical Devices Agency to discuss these results and identify the next steps for a phase III program in Japan. Apart from this, Ube Industries and Santen Pharmaceutical in Japan developed a famous ophthalmic product known as Omidenepag isopropyl ophthalmic solution 0.002 %, which is marketed under the name of EYBELIS is a selective prostaglandin E2 receptor 2 agonist with a non-prostaglandin structure for the treatment of glaucoma and ocular hypertension. Open-angle glaucoma – Market Outlook The Open-angle glaucoma (OAG) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. As per the assessment by DelveInsight’s analysts, it has been observed that the market size of OAG was observed to be USD 3,316.71 million in2017, in the 7MM. Among all the seven major markets, the United States covers the major market share that accounts for 41.01% of the 7MM. In 2017, the market size was accessed to be USD 1,360.30 million in the country. The products which are anticipated to be launched in the 7MM include Bimatoprost SR (Sustained-Release; Allergan), DE-117 (omidenepag isopropyl; Santen Pharmaceutical); PRO-122 (Laboratorios Sophia); PDP –

3. 716 (Brimonidine; Sun Pharma); Sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics) and Nyxol (Phentolamine Mesylate: Ocuphire Pharma). However, in addition to this, it is anticipated that Aerie Pharma with its two products ROCKLATAN and RHOPRESSA/Rhokiinsa will definitely show an impact on the open-angle glaucoma market of Europe. Recently, in November 2019, the European Commission (EC) granted marketing authorization to Rhokiinsa 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension. Besides thisSun Pharma Advanced Research Company (SPARC)is also expecting the launchof its product PDP – 716 (Brimonidine). In addition to this, a product named), DE-130A (of Santen Pharmaceutical is also anticipated to be launched in the European countries. ROCKLATAN and RHOPRESSA are approved in the US and recently Aerie pharma received a positive opinion from the CHMP. This positive opinion will help in the smooth launch of RHOPRESSA(underthe nameRHOKIINSA). Some of these products have completed the late clinical stages of development, while others are in ongoing late clinical development stages. These drug candidates have shown very promising results and it has been anticipated by DelveInsight’s analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of OAG will have better management practices. Open-angle glaucoma (OAG) – Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. The current therapeutic landscape of advanced stage OAG in the 7MM is driven by several approved therapies, including those with generic products. Of this, majority of the market share is accommodated by Prostaglandin analogs generating USD 1,806.12 million, followed by Carbonic anhydrase inhibitors generating USD 578.42 million while Miotics contributed the least towards the market share, with USD 146.31 million. To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of OAG during our forecast period, including In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP – 716 (Sun Pharma.), DE-130A (Santen), and others. Key Benefits • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Open-angle glaucoma market • • Organize sales and marketing efforts by identifying the best opportunities for Open-angle glaucoma market To understand the future market competition in the Open-angle glaucoma market. Request for sample pages: https://www.delveinsight.com/report-store/open-angle-glaucoma-market